Leuprorelin acetate depot vs danazol in the treatment of endometriosis: results of an open multicentre trial.

Abstract

A national multicentre trial was organized in order to compare the efficacy and safety of leuprorelin acetate depot and danazol in the treatment of endometriosis. Sixty-seven patients with pelvic endometriosis of different severity at laparoscopy were included in the study and followed during the 24 weeks of treatment. Leuprorelin acetate depot 3.75 mg was injected every 24 days, while the daily dose of danazol was 600-800 mg. At the end of the study objective improvements induced by the two drugs were observed by a second laparoscopic examination. In addition, at regular intervals during the study semiquantitative evaluation of subjective symptoms were monitored. Scoring the final objective changes in the two patient groups revealed no significant difference, however the women treated with leuprorelin acetate depot registered significantly better control of pelvic pain. Due to its efficacy, tolerability and ease of use, leuprorelin acetate appears to be an excellent drug for the treatment of endometriosis.

• Authors: P G Crosignani, A Gastaldi, P L Lombardi, U Montemagno, M Vignali, G B Serra, C Stella
• Journal: Clinical therapeutics (Clin Ther) Vol. 14 Suppl A Pg. 29-36 ( 1992) ISSN: 0149-2918 [Print] United States
• PMID: 1535020 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Delayed-Action Preparations
• Leuprolide
• Danazol

Topics

• Adult
• Danazol (adverse effects, therapeutic use)
• Delayed-Action Preparations
• Endometriosis (drug therapy)
• Female
• Humans
• Italy
• Laparoscopy
• Leuprolide (adverse effects, therapeutic use)
• Pelvic Neoplasms (drug therapy)